Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (GB:0LB2)
LSE:0LB2
RESEARCH TOOLSreports
Supernus Pharmaceuticals (0LB2) Share Price & Analysis
0 Followers
0LB2 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.54 - $35.33
Previous Close$30.71
Volume12.00
Average Volume (3M)228.00
Market Cap
$1.69B
Enterprise Value$1.43B
Total Cash (Recent Filing)$297.74M
Total Debt (Recent Filing)$32.99M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 06, 2024EPS Estimate
$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,974,254
10 Day Avg. Volume15
30 Day Avg. Volume228
Standard Deviation0.13
R-Squared0.18
Alpha0.00401
Financial Highlights & Ratios
Price to Book (P/B)6.40
Price to Sales (P/S)2.44
Price to Cash Flow (P/CF)9.70
P/FCF Ratio9.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda16.04
Forecast
1Y Price Target
$40.67Price Target Upside32.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Supernus Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
28.70% Insiders
34.94% Mutual Funds
32.25% Other Institutional Investors
4.12% Public Companies and
Individual Investors
0LB2 FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest share price was $22.54 and its highest was $35.33 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Currently, no data Available
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 10 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on May 08, 2024. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.262 by -$0.262.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is $0.39.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 54,974,255 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.262. Following the earnings report the stock price went down -3.022%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Woodline Partners LP. It holds Supernus Pharmaceuticals’s shares valued at 44M.
---
Supernus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.67 (32.43% Upside)
$40.67 (32.43% Upside)
Blogger Sentiment
Bullish
GB:0LB2 Sentiment 66%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.85%
12-Months-Change
Fundamentals
Return on Equity
-1.68%
Trailing 12-Months
Asset Growth
-27.22%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
0LB2 Earnings Call
Q1 2024
0:00 / 0:00
---
0LB2 Stock 12 Month Forecast
Average Price Target
$40.67
▲(32.43% Upside)
Technical Analysis
Supernus Pharmaceuticals
―
Alkermes
―
Arvinas Holding Company
―
PTC Therapeutics
―
BioMarin Pharmaceutical
―
Best Analysts Covering 0LB2
1 Year
1 Year Success Rate
14/22 ratings generated profit
1 Year Average Return
+3.05%
reiterated a buy rating 2 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +3.05% per trade.
---